Trial Profile

A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baclofen/naltrexone/sorbitol (Primary)
Indications Charcot-Marie-Tooth disease
Focus Registrational; Therapeutic Use
Acronyms PREMIER
Sponsors Pharnext

Most Recent Events

26 Jul 2024 This trial has been discontinued in Denmark (global end date: 2024-04-19), according to European Clinical Trials Database.
16 May 2024 This study has been Discontinued in France (End date:2023-12-12), according to European Clinical Trials Database record
02 Apr 2024 Planned End Date changed from 31 Mar 2024 to 19 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com